Get the Stockscreener App
68.43
2.75%
1.83
After Hours:
68.53
0.10
+0.15%
Dexcom Inc stock is traded at $68.43, with a volume of 4.72M.
It is up +2.75% in the last 24 hours and up +1.45% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$66.60
Open:
$67.05
24h Volume:
4.72M
Relative Volume:
0.99
Market Cap:
$26.84B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
47.90
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+4.95%
1M Performance:
+1.45%
6M Performance:
-0.20%
1Y Performance:
-5.46%
1-Day Range:
$66.70
$68.47
1-Week Range:
$63.20
$68.47
52-Week Range:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
68.43 | 26.12B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
129.51 | 223.72B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.53 | 147.05B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
381.22 | 143.14B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.92 | 122.86B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
75.29 | 43.82B | 5.69B | 1.41B | 577.90M | 6.9828 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom (DXCM) Receives Positive Coverage with Buy Rating and $85 Target - GuruFocus
Will DexCom Inc. (DC4) stock profit from AI boomTrade Signal Summary & Weekly Stock Performance Updates - nchmf.gov.vn
DexCom Inc. stock daily chart insightsOil Prices & Reliable Trade Execution Plans - newser.com
Can technical indicators confirm DexCom Inc.’s reversalJuly 2025 Closing Moves & Short-Term Trading Alerts - newser.com
Dexcom faces proposed class action suit over G7 CGM problems - MedTech Dive
What drives DexCom Inc DC4 stock priceMarket Profile Overview & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
Will DexCom Inc. (DC4) stock outperform energy sector in 2025Quarterly Trade Review & AI Driven Stock Movement Reports - newser.com
Will a bounce in DexCom Inc. offer an exitPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
What does recent volatility data suggest for DexCom Inc.Market Risk Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Will DexCom Inc. stock maintain momentum in 20252025 Top Gainers & Verified Entry Point Signals - newser.com
Should I buy DexCom Inc. (DC4) stock before earnings season2025 Trading Recap & Weekly Watchlist for Hot Stocks - newser.com
Is DexCom Inc. stock reversal real or fakeMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Key metrics from DexCom Inc.’s quarterly dataCEO Change & Long-Term Capital Growth Strategies - newser.com
Applying big data sentiment scoring on DexCom Inc.July 2025 Selloffs & Safe Entry Momentum Tips - newser.com
DexCom Inc. stock chart pattern explainedQuarterly Market Review & Verified Entry Point Signals - newser.com
What MACD and RSI say about DexCom Inc.Bond Market & Smart Investment Allocation Insights - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc.DXCM - Eastern Progress
What MACD trends signal for DexCom Inc. (DC4) stockMarket Risk Summary & Proven Capital Preservation Methods - newser.com
DexCom continues decline following FDA warning letter - MSN
Is DexCom Inc. stock near bottom after decline2025 Support & Resistance & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Why DexCom Inc. stock remains on watchlists2025 Fundamental Recap & Weekly Chart Analysis and Trade Guides - nchmf.gov.vn
Can DexCom Inc. (DC4) stock deliver consistent EPS growthWeekly Trade Report & AI Based Buy/Sell Signal Reports - Trung tâm Dự báo KTTV quốc gia
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom is facing a class action suit related to G7 CGM - MassDevice
US Market Recap: Can DexCom Inc. stock deliver sustainable ROE2025 Analyst Calls & Risk Controlled Daily Plans - nchmf.gov.vn
Aug Levels: What market sentiment indicators show for DexCom Inc. (DC4) stock2025 Winners & Losers & Low Drawdown Investment Strategies - nchmf.gov.vn
What catalysts could drive DexCom Inc. stock higherDay Trade & AI Forecasted Entry/Exit Points - newser.com
Dexcom Hit With Class Action Over Faulty Glucose Monitors - USA Herald
Dexcom Faces Class Action Over Glucose Monitor Tech - Law360
Is DexCom Inc. stock ready for a breakoutProfit Target & Weekly Momentum Stock Picks - newser.com
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength - Benzinga
Here’s Why Artisan Mid Cap Fund Exited Dexcom (DXCM) - Insider Monkey
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
Truist Securities Lowers Price Target for DexCom (DXCM) to $94.0 - GuruFocus
Is DexCom Inc. a candidate for recovery playMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
Weaker Guidance Amid Strong Sales Might Change The Case For Investing In DexCom (DXCM) - Sahm
The Bull Case For DexCom (DXCM) Could Change Following Cautious Full-Year Outlook Amid Sector Selloff - Yahoo Finance
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):